Effect of Adrenocorticotropic Hormone on Vascular Endothelial Growth Factor Release in Children Study
Status:
Completed
Trial end date:
2019-01-31
Target enrollment:
Participant gender:
Summary
Bone disease and adrenal suppression are two of the many side effects of steroid use in
pediatrics. Evidence has shown that adrenocorticotropic hormone (ACTH) protects against the
adverse bone effects of steroids in animals and in vitro models, but this has not yet been
evaluated in humans. The proposed mechanism in these studies is that ACTH stimulates
osteoblasts in bone to release Vascular Endothelial Growth Factor (VEGF), which increases the
vascularity in high risk areas of bone. This can potentially be protective against
osteonecrosis and osteopenia, which can lead to bone fractures if not prevented. The VEGF
release can also be used to demonstrate that an administration of exogenous ACTH occurred.
This could be important in diagnosing adrenal insufficiency (AI). One of the tests to assess
central AI is the low-dose ACTH stimulation test (LDAST). This test has a high rate of false
positive results due to technical limitations. However, if an ACTH-stimulated VEGF level can
be measured during the test as a marker of the test being done properly, it will allow for
proper interpretation of the results (and identification of a false positive), which will
reduce the number of patients being incorrectly diagnosed with central AI.
This study will recruit ten healthy children and adolescents, ages 9-18, to assess the
effects of ACTH on VEGF levels. The investigators will measure the response of VEGF and
cortisol to an administration of a low dose and high dose of cosyntropin (the synthetic ACTH
analog used in this test). The hypothesis of this study is that VEGF and cortisol will both
increase after administration of cosyntropin. At this time, no other studies have
demonstrated that VEGF is responsive to ACTH in humans. If the hypothesis is correct, the
results will have two main implications. VEGF can be used as a marker of ACTH administration
during the LDAST to identify false positive tests. Secondly, this will help further research
into whether ACTH can be used to protect against bone disease in high-dose steroid-treated
patients. Further studies can be done to assess whether this effect will be the same in
patients with AI or steroid-induced adrenal suppression.